Previous 10 | Next 10 |
2024-06-10 15:47:08 ET Moderna, Inc. (MRNA) Goldman Sachs 45th Annual Global Healthcare Conference June 10, 2024, 01:20 PM ET Company Participants Stephen Hoge - President Conference Call Participants Salveen Richter - Goldman Sachs Presentation ...
2024-06-10 14:58:39 ET More on CSL, bird flu Bird flu death in Mexico linked to strain not seen in humans before Travere, CSL win conditional nod for kidney disease therapy in EU Seeking Alpha’s Quant Rating on CSL Historical earnings data for CSL ...
2024-06-10 08:10:22 ET Moderna ( NASDAQ: MRNA ) said Monday that its investigational combination vaccine to protect against both COVID-19 and influenza elicited higher immune responses in adults 50 years and older compared to licensed comparator vaccines used in a late-stage trial.....
mRNA-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines in adults 50 years and older, including an enhanced influenza vaccine in adults 65 years and older CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / ...
2024-06-10 05:50:00 ET Some investors might view Moderna (NASDAQ: MRNA) as a shooting star that shined bright for a while then flamed out. In 2022, the biotech company generated sales of nearly $18.9 billion, but it expects revenue of only $4 billion this year. The real story fo...
2024-06-09 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-08 07:45:22 ET More on GSK, Agenus, etc. Agenus: Multiple Milestones In The Second Half Of 2024 GSK plc: Long-Term Cash Cow GSK Breathes New Life Into Asthma Treatment With Depemokimab GSK buys RNA therapeutics company for up to $50M Bird...
2024-06-07 12:11:30 ET More on BioNTech, Moderna, etc. Pfizer: Surging Cancer Rates Will Boost Revenues Moderna, Inc. (MRNA) Jefferies 2024 Global Healthcare Conference (Transcript) Pfizer: Too Early For A Turnaround Moderna mRNA candidate chosen for FDA rare...
Manufacturing is underway and doses of Moderna's Spikevax 2024-2025 formula will be ready to ship as early as August, pending regulatory approval CAMBRIDGE, MA / ACCESSWIRE / June 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an application to the U.S. Food and...
2024-06-07 10:10:00 ET June 7, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of viruses, featuring Aethlon Medical, Inc. (Nasdaq: AEMD ), a medical the...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...